Pfizer submitted data to the UK drugs regulator to get approval for the use of its coronavirus vaccine in 12 to 15-year-olds.
The US drug maker confirmed it was in contact with the London-based Medicines and Healthcare products Regulatory Agency (MHRA) over the use of its drug in teenagers.
A Pfizer representative told The National it submitted data on the efficacy of the vaccine in people aged 12 to 15 as part of an ongoing approval process.
The MHRA did not comment.
The vaccine, developed along with Germany's BioNTech, is approved for young people in the US and Canada.
Branded Comirnaty, Pfizer's vaccine is subject to an EU review for children 12 to 15 years old, with approval expected at the end of May.
The vaccine, which delivers instructions to the human body to build immunity against Covid-19, is also being tested in children aged 2 to 11.
Data on that trial is expected in September, Pfizer said.
Britain's vaccination campaign has been highly successful, with 54 million vaccines administered to more than 35.5 million people.
Only adults and the clinically vulnerable have been offered inoculation by the National Health Service.
As under-12s are less susceptible to Covid-19, the NHS has not announced plans for a wide-scale vaccination programme for children.
